Sandra Crnko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra Crnko has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Linda Wilhelmina Van Laake
Department of Cardiology and Transplantation Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands
5 shared publications - Niels Bovenschen
Department of Pathology University Medical Center Utrecht Utrecht the Netherlands
4 shared publications Toine Ten Broeke
Department of Pathology, University Medical Center Utrecht , Utrecht
4 shared publicationsBastiaan C. du Pré
Division of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
3 shared publicationsJan Meeldijk
Department of Pathology, University Medical Center Utrecht , Utrecht
3 shared publications- Pieter Afm Doevendans
Netherlands Heart Institute (NLHI), Utrecht, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Immune cell engager therapy for brain cancer
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first-line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.
- 18 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessImmune cell engager therapy for brain cancer
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first-line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.
- 14 February 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (2) , 282-283
Undergraduate education as catalyst for public–private partnership in biotechnology
- 14 February 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (2) , 282-283
Undergraduate education as catalyst for public–private partnership in biotechnology
- Open Access
- 16 October 2024
- Published by Elsevier in EBioMedicine
- Vol. 109, 105395
Integration of circadian rhythms and immunotherapy for enhanced precision in brain cancer treatment
- 16 October 2024
- Published by Elsevier in EBioMedicine
- Vol. 109, 105395
Open AccessIntegration of circadian rhythms and immunotherapy for enhanced precision in brain cancer treatment
- Open Access
- 15 October 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (11)
Uniting education, research, healthcare, and society to advance women’s heart health
Complex health challenges require professionals to operate across disciplines and to better connect with society. Here, we showcase a community-engaged and challenge-based educational model in which undergraduate students conduct transdisciplinary research on authentic complex biomedical problems. This concept reinforces translational medicine, human capital, and exemplifies synergy between education, research, healthcare, and society.
- 15 October 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (11)
Open AccessUniting education, research, healthcare, and society to advance women’s heart health
Complex health challenges require professionals to operate across disciplines and to better connect with society. Here, we showcase a community-engaged and challenge-based educational model in which undergraduate students conduct transdisciplinary research on authentic complex biomedical problems. This concept reinforces translational medicine, human capital, and exemplifies synergy between education, research, healthcare, and society.
- Open Access
- 17 April 2023
- Published by Elsevier in EBioMedicine
- Vol. 91, 104556
The circadian clock remains intact, but with dampened hormonal output in heart failure
- 17 April 2023
- Published by Elsevier in EBioMedicine
- Vol. 91, 104556
Open AccessThe circadian clock remains intact, but with dampened hormonal output in heart failure
- Open Access
- 25 May 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 869512
Circadian Dependence of the Acute Immune Response to Myocardial Infarction
Circadian rhythms influence the recruitment of immune cells and the onset of inflammation, which is pivotal in the response to ischemic cardiac injury after a myocardial infarction (MI). The hyperacute immune response that occurs within the first few hours after a MI has not yet been elucidated. Therefore, we characterized the immune response and myocardial damage 3 hours after a MI occurs over a full twenty-four-hour period to investigate the role of the circadian rhythms in this response. MI was induced at Zeitgeber Time (ZT) 2, 8, 14, and 20 by permanent ligation of the left anterior descending coronary artery. Three hours after surgery, animals were terminated and blood and hearts collected to assess the immunological status and cardiac damage. Blood leukocyte numbers varied throughout the day, peaking during the rest-phase (ZT2 and 8). Extravasation of leukocytes was more pronounced during the active-phase (ZT14 and 20) and was associated with greater chemokine release to the blood and expression of adhesion molecules in the heart. Damage to the heart, measured by Troponin-I plasma levels, was elevated during this time frame. Clock gene oscillations remained intact in both MI-induced and sham-operated mice hearts, which could explain the circadian influence of the hyperacute inflammatory response after a MI. These findings are in line with the clinical observation that patients who experience a MI early in the morning (i.e., early active phase) have worse clinical outcomes. This study provides further insight on the immune response occurring shortly after an MI, which may contribute to the development of novel and optimization of current therapeutic approaches.
- 25 May 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 869512
Open AccessCircadian Dependence of the Acute Immune Response to Myocardial Infarction
Circadian rhythms influence the recruitment of immune cells and the onset of inflammation, which is pivotal in the response to ischemic cardiac injury after a myocardial infarction (MI). The hyperacute immune response that occurs within the first few hours after a MI has not yet been elucidated. Therefore, we characterized the immune response and myocardial damage 3 hours after a MI occurs over a full twenty-four-hour period to investigate the role of the circadian rhythms in this response. MI was induced at Zeitgeber Time (ZT) 2, 8, 14, and 20 by permanent ligation of the left anterior descending coronary artery. Three hours after surgery, animals were terminated and blood and hearts collected to assess the immunological status and cardiac damage. Blood leukocyte numbers varied throughout the day, peaking during the rest-phase (ZT2 and 8). Extravasation of leukocytes was more pronounced during the active-phase (ZT14 and 20) and was associated with greater chemokine release to the blood and expression of adhesion molecules in the heart. Damage to the heart, measured by Troponin-I plasma levels, was elevated during this time frame. Clock gene oscillations remained intact in both MI-induced and sham-operated mice hearts, which could explain the circadian influence of the hyperacute inflammatory response after a MI. These findings are in line with the clinical observation that patients who experience a MI early in the morning (i.e., early active phase) have worse clinical outcomes. This study provides further insight on the immune response occurring shortly after an MI, which may contribute to the development of novel and optimization of current therapeutic approaches.
- Open Access
- 11 January 2022
- Published by Utrecht University Library
- p. 1-240
Through the multidimensional looking glass: Novel perspectives on heart failure
- 11 January 2022
- Published by Utrecht University Library
- p. 1-240
Open AccessThrough the multidimensional looking glass: Novel perspectives on heart failure
- Open Access
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009818
Noncytotoxic functions of killer cell granzymes in viral infections
Cytotoxic lymphocytes produce granules armed with a set of 5 serine proteases (granzymes (Gzms)), which, together with the pore-forming protein (perforin), serve as a major defense against viral infections in humans. This granule-exocytosis pathway subsumes a well-established mechanism in which target cell death is induced upon perforin-mediated entry of Gzms and subsequent activation of various (apoptosis) pathways. In the past decade, however, a growing body of evidence demonstrated that Gzms also inhibit viral replication and potential reactivation in cell death–independent manners. For example, Gzms can induce proteolysis of viral or host cell proteins necessary for the viral entry, release, or intracellular trafficking, as well as augment pro-inflammatory antiviral cytokine response. In this review, we summarize current evidence for the noncytotoxic mechanisms and roles by which killer cells can use Gzms to combat viral infections, and we discuss the potential thereof for the development of novel therapies.
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009818
Open AccessNoncytotoxic functions of killer cell granzymes in viral infections
Cytotoxic lymphocytes produce granules armed with a set of 5 serine proteases (granzymes (Gzms)), which, together with the pore-forming protein (perforin), serve as a major defense against viral infections in humans. This granule-exocytosis pathway subsumes a well-established mechanism in which target cell death is induced upon perforin-mediated entry of Gzms and subsequent activation of various (apoptosis) pathways. In the past decade, however, a growing body of evidence demonstrated that Gzms also inhibit viral replication and potential reactivation in cell death–independent manners. For example, Gzms can induce proteolysis of viral or host cell proteins necessary for the viral entry, release, or intracellular trafficking, as well as augment pro-inflammatory antiviral cytokine response. In this review, we summarize current evidence for the noncytotoxic mechanisms and roles by which killer cells can use Gzms to combat viral infections, and we discuss the potential thereof for the development of novel therapies.
- Open Access
- 31 March 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (3) , 1224-1233
Prognostic Biomarker Soluble ST2 Exhibits Diurnal Variation in Chronic Heart Failure Patients
Aim Soluble suppression of tumorigenicity‐2 (sST2) is a strong prognostic biomarker in heart failure. The emerging understanding of circadian biology in cardiovascular disease may lead to novel applications in prognosis and diagnosis and may provide insight into mechanistic aspects of the disease–biomarker interaction. So far, it is unknown whether sST2 exhibits a diurnal rhythm. Repeated measurements of sST2 may aid in clinical decision making. The goal of this study was to investigate whether sST2 exhibits diurnal variation in patients with heart failure with reduced ejection fraction (HFrEF) and in control subjects, thereby enhancing its diagnostic and prognostic values. Methods and results The study comprised 32 subjects: 16 HFrEF patients and 16 controls. Blood was collected at seven subsequent time points during a 24 h time period. sST2, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), melatonin, and cortisol were measured from serum. Peak values of sST2 clustered at daytime (modal value: 5 p.m.) in 87.6% of all subjects (81.3% of patients, P = 0.021; 93.8% of controls, P = 0.001), and minimum concentrations at night‐time (modal value: 5 a.m.) in 84.4% (87.5% of patients, P = 0.004 81.3% of controls, P = 0.021). A cosinor analysis of mean normalized sST2 values revealed significant cosine shaped 24 h oscillations of patients (P = 0.026) and controls (P = 0.037). NT‐proBNP in contrast did not show a diurnal rhythm, while melatonin and cortisol patterns were intact in all subjects. Conclusions sST2 exhibits a diurnal rhythm with lower values in the morning than in the late afternoon. This new insight could lead to refinement of its diagnostic and prognostic values through specified and consistent sampling times with repeated measurements. For example, by measuring sST2 during the afternoon, when levels are at their highest, false negatives on prognosis prediction could be avoided.
- 31 March 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (3) , 1224-1233
Open AccessPrognostic Biomarker Soluble ST2 Exhibits Diurnal Variation in Chronic Heart Failure Patients
Aim Soluble suppression of tumorigenicity‐2 (sST2) is a strong prognostic biomarker in heart failure. The emerging understanding of circadian biology in cardiovascular disease may lead to novel applications in prognosis and diagnosis and may provide insight into mechanistic aspects of the disease–biomarker interaction. So far, it is unknown whether sST2 exhibits a diurnal rhythm. Repeated measurements of sST2 may aid in clinical decision making. The goal of this study was to investigate whether sST2 exhibits diurnal variation in patients with heart failure with reduced ejection fraction (HFrEF) and in control subjects, thereby enhancing its diagnostic and prognostic values. Methods and results The study comprised 32 subjects: 16 HFrEF patients and 16 controls. Blood was collected at seven subsequent time points during a 24 h time period. sST2, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), melatonin, and cortisol were measured from serum. Peak values of sST2 clustered at daytime (modal value: 5 p.m.) in 87.6% of all subjects (81.3% of patients, P = 0.021; 93.8% of controls, P = 0.001), and minimum concentrations at night‐time (modal value: 5 a.m.) in 84.4% (87.5% of patients, P = 0.004 81.3% of controls, P = 0.021). A cosinor analysis of mean normalized sST2 values revealed significant cosine shaped 24 h oscillations of patients (P = 0.026) and controls (P = 0.037). NT‐proBNP in contrast did not show a diurnal rhythm, while melatonin and cortisol patterns were intact in all subjects. Conclusions sST2 exhibits a diurnal rhythm with lower values in the morning than in the late afternoon. This new insight could lead to refinement of its diagnostic and prognostic values through specified and consistent sampling times with repeated measurements. For example, by measuring sST2 during the afternoon, when levels are at their highest, false negatives on prognosis prediction could be avoided.
- Top Cited Papers
- 22 February 2019
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 16 (7) , 437-447
Circadian rhythms and the molecular clock in cardiovascular biology and disease
The Earth turns on its axis every 24 h; almost all life on the planet has a mechanism — circadian rhythmicity — to anticipate the daily changes caused by this rotation. The molecular clocks that control circadian rhythms are being revealed as important regulators of physiology and disease. In humans, circadian rhythms have been studied extensively in the cardiovascular system. Many cardiovascular functions, such as endothelial function, thrombus formation, blood pressure and heart rate, are now known to be regulated by the circadian clock. Additionally, the onset of acute myocardial infarction, stroke, arrhythmias and other adverse cardiovascular events show circadian rhythmicity. In this Review, we summarize the role of the circadian clock in all major cardiovascular cell types and organs. Second, we discuss the role of circadian rhythms in cardiovascular physiology and disease. Finally, we postulate how circadian rhythms can serve as a therapeutic target by exploiting or altering molecular time to improve existing therapies and develop novel ones.
- 22 February 2019
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 16 (7) , 437-447
Top Cited PapersCircadian rhythms and the molecular clock in cardiovascular biology and disease
The Earth turns on its axis every 24 h; almost all life on the planet has a mechanism — circadian rhythmicity — to anticipate the daily changes caused by this rotation. The molecular clocks that control circadian rhythms are being revealed as important regulators of physiology and disease. In humans, circadian rhythms have been studied extensively in the cardiovascular system. Many cardiovascular functions, such as endothelial function, thrombus formation, blood pressure and heart rate, are now known to be regulated by the circadian clock. Additionally, the onset of acute myocardial infarction, stroke, arrhythmias and other adverse cardiovascular events show circadian rhythmicity. In this Review, we summarize the role of the circadian clock in all major cardiovascular cell types and organs. Second, we discuss the role of circadian rhythms in cardiovascular physiology and disease. Finally, we postulate how circadian rhythms can serve as a therapeutic target by exploiting or altering molecular time to improve existing therapies and develop novel ones.